Table 5.
Pharmacokinetic parameters of the optimized FBX-SNELTs compared to the marketed FBX tablets (mean ± SD; n = 6).
| PK Parameters | Optimized FBX-SNELTs | Marketed FBX Tablets |
|---|---|---|
| Cmax (ng/mL) | 1340.0 ± 134.0 | 773.5 ± 117.6 |
| Tmax (min) | 45.0 ± 0.0 | 120.0 ± 0.0 |
| t1/2 (h) | 4.0 ± 0.27 | 4.28 ± 0.50 |
| AUC0–t (ng/mL h) | 8885.9 ± 1578.3 | 6069.9 ± 1640.0 |
| AUC0–inf (ng/mL h) | 9068.6 ± 1590.0 | 6230.7 ± 1715.7 |
| AUMC0–inf (ng/mL h2) | 60,175.0 ± 12,212.0 | 46,481.8 ± 15,071.3 |
| Kel (h−1) | 0.173 ± 0.01 | 0.165 ± 0.02 |
| MRT (h) | 6.61 ± 0.19 | 7.39 ± 0.39 |
| Relative BA (%) | 146.4 | - |
Abbreviations: Cmax, the maximum plasma concentration; Tmax, Time to maximum plasma concentration; t1/2, the elimination half-life; AUC0–t, the area under the plasma concentration-time curve from zero time to the last measurable concentration; AUC0–inf, the area under the plasma concentration-time curve from zero time to the infinity; AUMC, the area under the first moment curve; Kel, the terminal elimination rate constant; MRT, the mean residence time; BA, the bioavailability.